Multiple Sclerosis

Basic Info on Treating Multiple Sclerosis With Laser Photobiomodulation TLT, Transcranial Laser Therapy

Many patients with MS, Multiple Sclerosis, are surprised to find that they have significant pains with their MS. Traditionally, pain is not a large component of the MS symptoms. However, soft tissue and musculoskeletal pains may be quite common. The pains associated with MS can be very successfully treated with high-dose laser therapy. However, this is purely treating the symptom, rather than the cause, of MS.

There is also theoretical potential for treating the root cause of Multiple Sclerosis with TLT. There is a remote, theoretical, untested possibility that laser TLT may be able to halt or even reverse the progression of MS within the brain and spinal cord. TLT, transcranial laser therapy, has been shown in a small series of patients to have potentially breakthrough results on PTSD and TBI symptoms including depression, sleeplessness, suicidal thoughts, and employment.

TLT is being investigated for use in multiple brain disorders including PTSD, TBI Traumatic Brain Injury, Depression, and Alzheimers.

TLT is thought to work by accelerating the mitochondrial production of ATP, improving cell metabolism. Additionally, there is evidence that laser stimulation increases secretion of NGF, nerve growth factor. In MS, there is some indication that ATP production is damaged, and that cell metabolism lags the auto-immune destruction of myelin.

In MS, there is some indication in *mouse* models that laser therapy may be helpful in halting the progression of MS. The clinical human studies are scant and underwhelming. See selected references below.

Here are results of TLT in a PTSD patient. Note the 90-95% reduction in PTSD and Depression scores over 3 weeks, and persisting after TLT therapy stopped.

Potential Treatment of MS with TLT

LaserMD Pain Relief, one of the nation’s leaders in high-dose laser pain treatment, can use TLT to treat selected MS patients. Key points:

TLT is unproven in MS. No reports of high-dose laser or TLT in humans.

Very selective criteria for receiving TLT.

Must be coordinated with your neurologist.

TLT is an off-label use of an FDA-cleared Class 4 medical laser.

Only available at the Santa Monica / St. John’s area location.

You must be able to come to the Santa Monica location 2-4 times per week for 4-8 weeks.

You must be computer literate and have ready access to email and web.+

Documentary & Testimonial on TLT Treatment of PTSD

The first patient treated in California with TLT for her PTSD had these results after four weeks:

Watch this 3 minute video documentary of a 4 week PTSD Treatment, and the before- and after- interview: TLT PTSD Treatment Video Documentary

Scientific Background of TLT in PTSD

View these two resources:

Information about TLT results to date, and a video explaining how TLT works.

Proposed Phase I trial of TLT in Veterans

Selected References for Treating MS Multiple Sclerosis with Laser, LLLT, or Photobiomodulation

Amelioration of Experimental Autoimmune Encephalomyelitis in C57BL/6 Mice by Photobiomodulation Induced by 670 nm Light

Type	Journal Article
Author	Kamaldeen A. Muili
Author	Sandeep Gopalakrishnan
Author	Stacy L. Meyer
Author	Janis T. Eells
Author	Jeri-Anne Lyons
URL	http://dx.doi.org/10.1371/journal.pone.0030655
Volume	7
Issue	1
Pages	e30655
Publication	PLoS ONE
Date	January 24, 2012
Journal Abbr	PLoS ONE
DOI	10.1371/journal.pone.0030655
Accessed	11/8/2015, 8:04:21 PM
Library Catalog	PLoS Journals
Abstract	Background The approved immunomodulatory agents for the treatment of multiple sclerosis (MS) are only partially effective. It is thought that the combination of immunomodulatory and neuroprotective strategies is necessary to prevent or reverse disease progression. Irradiation with far red/near infrared light, termed photobiomodulation, is a therapeutic approach for inflammatory and neurodegenerative diseases. Data suggests that near-infrared light functions through neuroprotective and anti-inflammatory mechanisms. We sought to investigate the clinical effect of photobiomodulation in the Experimental Autoimmune Encephalomyelitis (EAE) model of multiple sclerosis. Methodology/Principal Findings The clinical effect of photobiomodulation induced by 670 nm light was investigated in the C57BL/6 mouse model of EAE. Disease was induced with myelin oligodendrocyte glycoprotein (MOG) according to standard laboratory protocol. Mice received 670 nm light or no light treatment (sham) administered as suppression and treatment protocols. 670 nm light reduced disease severity with both protocols compared to sham treated mice. Disease amelioration was associated with down-regulation of proinflammatory cytokines (interferon-γ, tumor necrosis factor-α) and up-regulation of anti-inflammatory cytokines (IL-4, IL-10) in vitro and in vivo. Conclusion/Significance These studies document the therapeutic potential of photobiomodulation with 670 nm light in the EAE model, in part through modulation of the immune response.
Date Added	11/8/2015, 8:04:21 PM
Modified	11/8/2015, 8:11:37 PM

Attachments

Muili et al. - 2012 - Amelioration of Experimental Autoimmune Encephalom.pdf

[Application of laser therapy in the physiotherapy of patients with multiple sclerosis]

Type	Journal Article
Author	Anna Kubsik
Author	Paulina Klimkiewicz
Author	Marta Woldańska-Okońska
Volume	65
Issue	1
Pages	55-61
Publication	Wiadomości Lekarskie (Warsaw, Poland: 1960)
ISSN	0043-5147
Date	2012
Extra	PMID: 22827117
Journal Abbr	Wiad. Lek.
Library Catalog	PubMed
Language	pol
Abstract	Multiple sclerosis is a chronic disease of the nervous system, which main manifestations are disseminated demyelinated the changes in the central nervous system. The pathogenesis of this disease is still not known, the curative treatment is not possible. In connection with the alleged autoimmune genesis of MS patients are administered immunomodulatory drugs. Patients with multiple sclerosis suffer from a number of symptoms associated with this disease. The aim of this article is to present the main clinical symptoms characteristic of MS and to present biological effects of low-energy lasers used in the treatment of multiple sclerosis.
Date Added	11/8/2015, 8:07:50 PM
Modified	11/8/2015, 8:07:50 PM

Attachments

PubMed entry

Death of Myelin Creating Brain Cells May Trigger Multiple Sclerosis

Type	Web Page
Author	Neuroscience News
URL	http://neurosciencenews.com/oligodendrocytes-myelin-ms-neurology-3278/
Accessed	12/26/2015, 12:44:14 PM
Abstract	New study in mice finds the death of a specific class of brain cells triggers an MS-like immune response, which can be prevented by nanoparticle therapy.Multiple sclerosis (MS) may be triggered by
Website Title	Neuroscience News
Date Added	12/26/2015, 12:44:14 PM
Modified	12/26/2015, 12:44:14 PM

Notes:

Multiple sclerosis (MS) may be triggered by the death of brain cells that make myelin, the insulation around nerve fibers, according to research on a novel mouse model developed by scientists from the University of Chicago and Northwestern Medicine. The death of these cells initiates an autoimmune response against myelin, the main characteristic of the disease, which leads to MS-like symptoms in mice.

Attachments

Snapshot

Immunology of Relapse and Remission in Multiple Sclerosis

Type	Journal Article
Author	Lawrence Steinman
URL	http://www.annualreviews.org/doi/abs/10.1146/annurev-immunol-032713-120227
Volume	32
Issue	1
Pages	257-281
Publication	Annual Review of Immunology
ISSN	0732-0582, 1545-3278
Date	2014-03-21
DOI	10.1146/annurev-immunol-032713-120227
Accessed	11/8/2015, 8:08:41 PM
Library Catalog	CrossRef
Language	en
Date Added	11/8/2015, 8:08:41 PM
Modified	12/7/2017, 7:57:39 PM

Jeri-Anne Lyons | College of Health Sciences

Type	Blog Post
URL	http://uwm.edu/healthsciences/directory/lyons-jeri-anne/
Accessed	11/8/2015, 8:08:56 PM
Date Added	11/8/2015, 8:08:56 PM
Modified	11/8/2015, 8:08:56 PM

Attachments

Snapshot

Laser biostimulation of patients suffering from multiple sclerosis in respect to the biological influence of laser light

Type	Conference Paper
Author	Cezary Peszynski-Drews
Author	Andrzej Klimek
Author	Marek Sopinski
Author	Dominik Obrzejta
URL	http://dx.doi.org/10.1117/12.520611
Volume	5229
Pages	97-103
Date	2003
DOI	10.1117/12.520611
Accessed	11/8/2015, 8:06:39 PM
Library Catalog	Silverchair
Abstract	The authors discuss the results, obtained so far during three years' clinical examination, of laser therapy in the treatment of patients suffering from multiple sclerosis. They regard both the results of former laboratory experiments and so far discovered mechanisms of biological influence of laser light as an objective explanation of high effectiveness of laser therapy in the csae of this so far incurable disease. They discuss wide range of biological mechanisms of laser therapy, examined so far on different levels (cell, tissue, organ), allowing the explanation of beneficial influence of laser light in pathogenetically different morbidities.
Date Added	11/8/2015, 8:06:39 PM
Modified	11/8/2015, 8:06:39 PM

Attachments

Peszynski-Drews et al. - 2003 - Laser biostimulation of patients suffering from mu.pdf

Light therapy to treat autoimmune disease

Type	Journal Article
Author	Jeri-Anne Lyons
URL	http://www.spie.org/x113438.xml
Publication	SPIE Newsroom
ISSN	18182259
Date	2015-04-24
DOI	10.1117/2.1201504.005900
Accessed	11/8/2015, 8:08:41 PM
Library Catalog	CrossRef
Date Added	11/8/2015, 8:08:41 PM
Modified	12/7/2017, 7:56:57 PM

Attachments

Light therapy to treat autoimmune disease

LLLT for Multiple sclerosis (MS) : Nice work Jeri-Anne, Janis and Chukuka | THOR Low Level Laser Therapy LLLT Products and Training

Type	Web Page
URL	http://blog.thorlaser.com/lllt-for-multiple-sclerosis-ms-nice-work-jeri-anne-janis-and-chukuka/
Accessed	11/8/2015, 8:08:17 PM
Date Added	11/8/2015, 8:08:17 PM
Modified	11/8/2015, 8:08:17 PM

Attachments

LLLT for Multiple sclerosis (MS) : Nice work Jeri-Anne, Janis and Chukuka | THOR Low Level Laser Therapy LLLT Products and Training

Low-level laser therapy ameliorates disease progression in a mouse model of multiple sclerosis

Type	Journal Article
Author	Elaine D. Gonçalves
Author	Priscila S. Souza
Author	Vicente Lieberknecht
Author	Giulia S. P. Fidelis
Author	Rafael I. Barbosa
Author	Paulo C. L. Silveira
Author	Ricardo A. de Pinho
Author	Rafael C. Dutra
URL	https://doi.org/10.3109/08916934.2015.1124425
Volume	49
Issue	2
Pages	132-142
Publication	Autoimmunity
ISSN	0891-6934
Date	February 17, 2016
Extra	PMID: 26703077
DOI	10.3109/08916934.2015.1124425
Accessed	12/7/2017, 8:05:46 PM
Library Catalog	Taylor and Francis+NEJM
Abstract	Multiple sclerosis (MS) is an autoimmune demyelinating inflammatory disease characterized by recurrent episodes of T cell-mediated immune attack on central nervous system (CNS) myelin, leading to axon damage and progressive disability. The existing therapies for MS are only partially effective and are associated with undesirable side effects. Low-level laser therapy (LLLT) has been clinically used to treat inflammation, and to induce tissue healing and repair processes. However, there are no reports about the effects and mechanisms of LLLT in experimental autoimmune encephalomyelitis (EAE), an established model of MS. Here, we report the effects and underlying mechanisms of action of LLLT (AlGaInP, 660 nm and GaAs, 904 nm) irradiated on the spinal cord during EAE development. EAE was induced in female C57BL/6 mice by immunization with MOG35–55 peptide emulsified in complete Freund’s adjuvant. Our results showed that LLLT consistently reduced the clinical score of EAE and delayed the disease onset, and also prevented weight loss induced by immunization. Furthermore, these beneficial effects of LLLT seem to be associated with the down-regulation of NO levels in the CNS, although the treatment with LLLT failed to inhibit lipid peroxidation and restore antioxidant defense during EAE. Finally, histological analysis showed that LLLT blocked neuroinflammation through a reduction of inflammatory cells in the CNS, especially lymphocytes, as well as preventing demyelination in the spinal cord after EAE induction. Together, our results suggest the use of LLLT as a therapeutic application during autoimmune neuroinflammatory responses, such as MS.
Date Added	12/7/2017, 8:05:46 PM
Modified	12/7/2017, 8:07:15 PM

Attachments

Snapshot

Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients

Type	Journal Article
Author	Ranjan Dutta
Author	Jennifer McDonough
Author	Xinghua Yin
Author	John Peterson
Author	Ansi Chang
Author	Thalia Torres
Author	Tatyana Gudz
Author	Wendy B. Macklin
Author	David A. Lewis
Author	Robert J. Fox
Author	Richard Rudick
Author	Karoly Mirnics
Author	Bruce D. Trapp
URL	http://doi.wiley.com/10.1002/ana.20736
Volume	59
Issue	3
Pages	478-489
Publication	Annals of Neurology
ISSN	03645134, 15318249
Date	03/2006
DOI	10.1002/ana.20736
Accessed	11/8/2015, 8:08:41 PM
Library Catalog	CrossRef
Language	en
Date Added	11/8/2015, 8:08:41 PM
Modified	12/7/2017, 8:01:27 PM

Attachments

Dutta et al. - 2006 - Mitochondrial dysfunction as a cause of axonal deg.pdf